Pandemic Control Industry - Therapeutics

Home / Pandemic Control
Company Product R&D / Approval Status
PharmaEssentia Besremi (P1101) Approved in EU for treatment of Polycythemia Vera (PV); Apply for the FDA’s Coronavirus Treatment Acceleration Program
TaiGen Biotechnology Taigexyn® (Nemonoxacin) Approved new drug for treatment of drug-resistant bacterial infection in Taiwan and China; Treatment for recurrent pneumonia of COVID-19 patients.
GoldenBiotech Antroquinonol (Hocena) Phase II US IND-approved for mild and moderate COVID-19 patients
Senhwa Biosciences Silmitasertib (CX-4945) Phase II for cholangiocarcinoma in US, KR, TW; Named by QBI Coronavirus Research Group (QCRG) as Potential Covid-19 Therapy
Academia Sinica 3C-like Protease Inhibitors Research (cell-based assay)
National Chung Hsing University (NCHU) 5-benzyloxygramine Discovery
Mycenax LusiNEX (biosimilar of tocilizumab) FDA has approved a randomized phase III of intravenous tocilizumab (Actemra) plus standard of care in hospitalized adult patients with pneumonia as a complication of COVID-19